Optimistic Buy Rating for Acurx Pharmaceuticals Driven by Promising Ibezapolstat Progress and Strategic Financial Planning
Acurx Pharmaceuticals to Present at the Microcap Conference, January 28, 2025 - January 30, 2025
Acurx Pharmaceuticals Analyst Ratings
Express News | Acurx Pharmaceuticals Shares Are Trading Higher After the Company Announced Its Preparing to Advance to Phase 3 Clinical Trials to Treat Patients With C. Difficile Infection
Express News | Acurx Pharmaceuticals Inc - FDA Provides Positive Feedback on Acurx's Cmc Plan for Phase 3
Acurx Updates Phase 3 Readiness for Ibezapolstat in C. Difficile Infection Based on Recent FDA and EMA Communications
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
